SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:liu-88362"
 

Sökning: id:"swepub:oai:DiVA.org:liu-88362" > Predictive role of ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006890naa a2200769 4500
001oai:DiVA.org:liu-88362
003SwePub
008130204s2013 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:d8ccfc3f-d411-4edf-9178-c027644019ae
009oai:gup.ub.gu.se/173272
009oai:DiVA.org:uu-191988
009oai:prod.swepub.kib.ki.se:125900221
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-883622 URI
0247 a https://doi.org/10.1016/j.ejca.2012.07.0322 DOI
0247 a https://lup.lub.lu.se/record/34810612 URI
0247 a https://gup.ub.gu.se/publication/1732722 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1919882 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1259002212 URI
040 a (SwePub)liud (SwePub)lud (SwePub)gud (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Sörenson, Sverreu Östergötlands Läns Landsting,Linköpings universitet,Lungmedicin,Hälsouniversitetet,Lungmedicinska kliniken US,Allergicentrum US4 aut0 (Swepub:liu)sveso28
2451 0a Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy
264 1b Elsevier,c 2013
338 a electronic2 rdacarrier
500 a Funding Agencies|Ostergotland County Council, Medical Research Council of South-East Sweden (FORSS)||
520 a Aim of the study: The primary purpose of this study is to investigate if pretreatment plasma levels of vascular endothelial growth factor (VEGF) are predictive of the effect of celecoxib on survival in advanced non-small cell lung cancer (NSCLC) treated with palliative chemotherapy. A secondary objective is to describe the course of plasma VEGF levels during and after treatment with cytotoxic chemotherapy combined with celecoxib or placebo. less thanbrgreater than less thanbrgreater thanMethods: In a previously published double-blind multicenter phase III trial, 316 patients with NSCLC stage IIIB or IV and World Health Organisation (WHO) performance status 0-2 were randomised to receive celecoxib 400 mg b.i.d. or placebo in combination with two-drug platinum-based chemotherapy. Chemotherapy cycle length was three weeks and planned duration of chemotherapy was four cycles. Celecoxib was given for a maximum of one year but was stopped earlier in case of disease progression or prohibitive toxicity. In a subset of patients, plasma VEGF levels were examined at onset of treatment and at 6, 12 and 20 weeks. less thanbrgreater than less thanbrgreater thanResults: VEGF levels at start of treatment were obtained in 107 patients at four study sites. The median value was 70 pg/ml. Mean values declined during the first 12 weeks and then increased at 20 weeks. A subpopulation treatment effect pattern plot (STEPP) analysis showed an inverse relationship between initial plasma VEGF and the impact of celecoxib on survival with zero effect at 200 pg/ml. The effect on survival by celecoxib in the whole subset of patients was positive (hazard ratio (HR)=0.64 [confidence interval (CI) 0.43-0.95], p=0.028). less thanbrgreater than less thanbrgreater thanConclusion: Low pretreatment plasma levels of VEGF appear to be predictive of a positive effect of celecoxib on survival.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Lungmedicin och allergi0 (SwePub)302192 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Respiratory Medicine and Allergy0 (SwePub)302192 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Non-small cell lung cancer
653 a Celecoxib
653 a Chemotherapy
653 a Survival
653 a Plasma VEGF
653 a MEDICINE
653 a MEDICIN
653 a Non-small cell lung cancer
653 a Celecoxib
653 a Chemotherapy
653 a Survival
653 a Plasma
653 a VEGF
7001 a Fohlin, Helenau Östergötlands Läns Landsting,Linköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet,Regionalt cancercentrum4 aut0 (Swepub:liu)helfo18
7001 a Lindgren, Andreau Östergötlands Läns Landsting,Linköpings universitet,Internmedicin,Hälsouniversitetet,Allergicentrum US4 aut0 (Swepub:liu)andko90
7001 a Lindskog, Magnusu Karolinska Institutet,Uppsala universitet,Institutionen för radiologi, onkologi och strålningsvetenskap,Cancerfarmakologi och beräkningsmedicin,Uppsala University, Sweden4 aut0 (Swepub:uu)magli409
7001 a Bergman, Bengt,d 1953u Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine,Sahlgrens University Hospital, Sweden4 aut0 (Swepub:gu)xbeben
7001 a Sederholm, Christeru Östergötlands Läns Landsting,Linköpings universitet,Lungmedicin,Hälsouniversitetet,Lungmedicinska kliniken US4 aut0 (Swepub:liu)chrse81
7001 a Ek, Larsu Lund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital, Sweden4 aut0 (Swepub:lu)lung-lek
7001 a Lamberg, Kristinau Uppsala universitet,Lungmedicin och allergologi,University of Uppsala Hospital, Sweden4 aut0 (Swepub:uu)krila642
7001 a Clinchy, Birgittau Linköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet4 aut0 (Swepub:liu)bircl77
7102 a Linköpings universitetb Lungmedicin4 org
7730 t European Journal of Cancerd : Elsevierg 49:1, s. 115-120q 49:1<115-120x 0959-8049x 1879-0852
8564 u https://liu.diva-portal.org/smash/get/diva2:602881/FULLTEXT01.pdfx primaryx Raw objecty fulltext:postprint
8564 u http://liu.diva-portal.org/smash/get/diva2:602881/FULLTEXT01
8564 u http://dx.doi.org/10.1016/j.ejca.2012.07.032y FULLTEXT
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-88362
8564 8u https://doi.org/10.1016/j.ejca.2012.07.032
8564 8u https://lup.lub.lu.se/record/3481061
8564 8u https://gup.ub.gu.se/publication/173272
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-191988
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:125900221

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy